On January 19, 2024 Novartis reported data from the Phase III NETTER-2 trial showing that Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus long-acting release (LAR) octreotide reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose octreotide LAR alone (Press release, Novartis, JAN 19, 2024, View Source [SID1234639366]). Data were presented at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal (GI) Cancers Symposium.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy for newly diagnosed patients living with these types of advanced GEP-NETs," said Dr. Simron Singh, Associate Professor of Medicine at the University of Toronto and cofounder of the Susan Leslie Clinic for Neuroendocrine Tumours at the Odette Cancer Centre, Sunnybrook Health Sciences Centre, Ontario, Canada. "These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer."

Efficacy endpoint1 Lutathera plus octreotide LAR vs. high-dose octreotide LAR
Progression-free survival HR 0.28 (95% CI: 0.18, 0.42; p<0.0001)
Median PFS (months) 22.8 month (95% CI: 19.4 -not estimable) vs. 8.5 months (95% CI: 7.7-13.8)
Objective response rate (ORR)* 43% (95% CI: 35.0-51.3) vs. 9.3% (95% CI: 3.8-18.3), p<0.0001
*Assessed via RECIST 1.1
"This is the first positive Phase III trial of a radioligand therapy in the first-line setting, and the overall efficacy and safety results are amongst the most clinically relevant observed to date in this kind of advanced cancer, addressing a significant unmet need for patients with newly diagnosed advanced GEP-NETs," said Jeff Legos, Global Head of Oncology Development at Novartis. "The positive results are a significant advancement and further reaffirm our strategy to research and develop radioligand therapies in earlier lines of treatment or stages of disease to improve outcomes for patients."

No new or unexpected safety findings were observed in the study and data are consistent with the already well-established safety profile of Lutathera1. Most patients (88%) in the Lutathera arm received all four cycles of Lutathera treatment. The most common all-grade AEs (≥20%) for the Lutathera arm vs. control arm were nausea (27.2% vs 17.8%), diarrhea (25.9% vs 34.2%) and abdominal pain (17.7% vs 27.4%), and the most common grade ≥3 AE (>5%) was lymphocyte count decreased (5.4% vs 0%).

NETs are a type of cancer that originate in neuroendocrine cells throughout the body and are commonly considered slow-growing malignancies. However, some NETs are associated with rapid progression and poor prognosis and in many cases, diagnosis is delayed until patients have advanced disease2-4. Even though NETs are a rare (orphan) disease, their incidence has increased over the past several decades2-5 and there is a need for continued research into treatment options for newly diagnosed patients.

The NETTER-2 trial is ongoing for further evaluation of secondary endpoints including overall survival and long-term safety.

About NETTER-2
NETTER-2 (NCT03972488) is an open-label, multi-center, randomized, comparator-controlled Phase III trial assessing whether Lutathera plus octreotide LAR when taken as a first-line treatment can prolong PFS in patients with high-proliferation rate tumors (G2 and G3), compared to treatment with high-dose (60 mg) long-acting octreotide6. Eligible patients were diagnosed with SSTR-positive advanced GEP-NETs within 6 months before enrollment6.

About Lutathera
Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) is approved in the US for the treatment of adult patients with SSTR-positive GEP-NETs, including those in the foregut, midgut and hindgut, an indication which includes the NETTER-2 population. Lutathera is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults7,8, and in Japan for SSTR-positive NETs.

On January 19, 2024 Astrazeneca reported that Positive results from the EMERALD-1 Phase III trial showed Imfinzi (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolisation (Press release, AstraZeneca, JAN 19, 2024, View Source [SID1234639367]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These results will be presented today at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, California (#LBA432).

Approximately 20-30% of patients with HCC, the most common type of liver cancer, are eligible for embolisation, a procedure that blocks the blood supply to the tumour and can also deliver chemotherapy or radiation therapy directly to the liver.1-8 Despite being the standard of care in this setting, most patients who receive embolisation experience disease progression or recurrence within eight months.9-11

In EMERALD-1, treatment with Imfinzi plus TACE and bevacizumab reduced the risk of disease progression or death by 23% compared to TACE alone (based on a hazard ratio [HR] of 0.77; 95% confidence interval [CI] 0.61-0.98; p=0.032). Median PFS was 15 months in patients treated with the Imfinzi combination versus 8.2 months with TACE. The PFS benefit observed was generally consistent across key prespecified subgroups. The secondary endpoint of time to progression (TTP) further supports the clinical benefit of Imfinzi plus TACE and bevacizumab in this setting, with a median TTP of 22 months versus 10 months for TACE (HR 0.63; 95% CI 0.48-0.82).

The trial will continue as planned to assess the key secondary endpoint of overall survival (OS).

Bruno Sangro, MD, PhD, Director of the Liver Unit and Professor of Medicine at Clínica Universidad de Navarra, Pamplona, Spain and a lead investigator in the EMERALD-1 trial, said: "In this earlier liver cancer setting, embolisation alone has been the standard of care for more than 20 years, and rates of disease progression have remained high. Adding durvalumab and bevacizumab to TACE reduced the risk of disease progression or death by twenty-three per cent for patients with liver cancer eligible for embolisation, showing for the first time that combining a systemic treatment with TACE meaningfully improves this clinically relevant outcome in earlier-stage disease."

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "With Imfinzi-based treatment, patients with liver cancer eligible for embolisation lived nearly seven additional months before their disease progressed. We are discussing these positive EMERALD-1 data with global regulatory authorities while awaiting the final overall survival results from the trial."

Summary of results: EMERALD-1i

Imfinzi plus TACE and bevacizumab

(n=204)

Placebo plus TACE

(n=205)

Median PFS (months; 95% CI)ii, iii

15.0 (11.1-18.9)

8.2 (6.9-11.1)

PFS HR (95% CI)ii, iv

0.77 (0.61-0.98)

p-valuev

0.032

PFS rate at 12 months (%)iii

55.5

39.8

PFS rate at 18 months (%)iii

43.1

28.3

Median TTP (months; 95% CI)iii, v

22.0 (16.6-24.9)

10.0 (7.1-13.6)

TTP HR (95% CI)iv, v

0.63 (0.48-0.82)

Subjects with measurable disease

Imfinzi plus TACE and bevacizumab

(n=202)

Placebo plus TACE

(n=203)

Objective Response Rate (ORR) (%)iii

43.6

29.6

i The data cut-off date was 11 Sep 2023.

ii PFS, TTP and ORR by Blinded Independent Central Review (BICR) per RECIST v1.1

iii Calculated using Kaplan-Meier method

iv Calculated from stratified Cox proportional hazards method

v The threshold of significance for this analysis was 0.0435 based on the alpha spend at the PFS interim analysis (2.27%) and the actual number of events at PFS final analysis.

The safety profile for Imfinzi plus TACE and bevacizumab was generally manageable and consistent with the known profile of each medicine. The number of TACE procedures was consistent across arms. No new safety signals were observed. Grade 3 and 4 adverse events due to any cause occurred in 45.5% of patients treated with Imfinzi plus TACE and bevacizumab and 23% of patients treated with TACE alone.

Notes

Liver cancer
Liver cancer, of which HCC is the most common type, is the third-leading cause of cancer death, with an estimated 900,000 people worldwide diagnosed each year and a high prevalence in certain regions of Asia.12-14 An estimated 80-90% of all patients with HCC also have cirrhosis.15 Chronic liver diseases such as cirrhosis are associated with inflammation that over time can lead to the development of HCC.15 Immunotherapy is a proven treatment modality in HCC with approved options available for patients in later-line settings.16

EMERALD-1
EMERALD-1 is a randomised, double-blind, placebo-controlled, multicentre, global Phase III trial of Imfinzi plus TACE concurrently, followed by Imfinzi with or without bevacizumab until progression versus TACE alone in a total of 616 patients with unresectable HCC eligible for embolisation.

The trial was conducted in 157 centres across 18 countries, including in North America, Australia, Europe, South America and Asia. The primary endpoint was PFS for Imfinzi plus TACE and bevacizumab versus TACE alone, and secondary endpoints include PFS for Imfinzi plus TACE, OS, patient-reported outcomes and ORR.

Imfinzi
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.

Imfinzi is approved in combination with chemotherapy (gemcitabine plus cisplatin) in locally advanced or metastatic biliary tract cancer (BTC) and in combination with Imjudo (tremelimumab) in unresectable HCC in the US, EU, Japan, China and many other countries based on the TOPAZ-1 and HIMALAYA Phase III trials, respectively. Following HIMALAYA in the advanced setting, EMERALD-1 is AstraZeneca’s second positive Phase III trial in HCC.

In non-small cell lung cancer (NSCLC), Imfinzi is approved in combination with a short course of Imjudo and chemotherapy for the treatment of metastatic NSCLC in the US, EU and Japan based on the POSEIDON Phase III trial. Imfinzi is also the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III NSCLC in patients whose disease has not progressed after chemoradiation therapy based on the PACIFIC Phase III trial, the results of which have been confirmed in the real-world setting in the PACIFIC-R study. In 2023, AstraZeneca announced positive results from the AEGEAN Phase III trial evaluating Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery in resectable NSCLC.

Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer (SCLC) based on the CASPIAN Phase III trial. Imfinzi is approved in previously treated patients with advanced bladder cancer in a small number of countries.

Since the first approval in May 2017, more than 200,000 patients have been treated with Imfinzi.

As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with SCLC, NSCLC, bladder cancer, several GI cancers, breast cancer and other solid tumours. In 2023, AstraZeneca announced positive results for several Phase III trials evaluating Imfinzi in various combinations, including in ovarian (DUO-O) and endometrial (DUO-E) cancers with Lynparza (olaparib).

In GI cancers specifically, AstraZeneca has an extensive clinical development programme further assessing Imfinzi across multiple settings. In addition to EMERALD-1, Imfinzi is also being investigated in combination with bevacizumab in adjuvant HCC (EMERALD-2), in combination with Imjudo, lenvatinib and TACE in embolisation-eligible HCC (EMERALD-3), in resectable gastric and gastroesophageal junction cancers (MATTERHORN) and in locally advanced oesophageal cancer (KUNLUN). In June 2023, Imfinzi added to standard-of-care neoadjuvant chemotherapy met a key secondary endpoint of pathologic complete response in the MATTERHORN Phase III trial.

On January 19, 2024 Jacobio Pharmaceuticals (1167.HK), a clinical-stage oncology company focusing on undruggable targets, reported data of glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium ("2024 ASCO (Free ASCO Whitepaper) GI") (Press release, Jacobio Pharmaceuticals, JAN 19, 2024, View Source [SID1234639369]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of December 6, 2023, the monotherapy global study of glecirasib enrolled 52 patients with pancreatic cancer and other solid tumors harboring KRAS G12C mutation in China, the United States, Europe, Israel and other regions, including 31 patients with pancreatic cancer, and 21 patients with other solid tumors (8 with biliary tract tumors, 3 with gastric cancer, 3 with small bowel cancer, 2 with appendix cancer, and 5 with other solid tumors).

Among 50 patients with evaluable solid tumors, the confirmed objective response rate (cORR) was 48% (24/50) and the disease control rate (DCR) was 90% (45/50). For second-line and above KRAS G12C mutated pancreatic cancer patients, the cORR was 41.9% (13/31) and the DCR was 93.5% (29/31). The median progression-free survival (mPFS) was 5.6 months, and the median overall survival (mOS) was 10.7 months. In other solid tumor patients, the cORR was 57.9% (11/19), DCR was 84.2% (16/19), the mPFS was 7.0 months, and the mOS has not yet matured. The above safety and efficacy data are better than the published data of similar studies.

Glecirasib has good tolerability and safety characteristics, the majority of treatment-related adverse events (TRAEs)are grades 1-2, and grade 3 or above TRAEs occurred in 25% of patients. No patient has permanently withdrawn from the study due to TRAE.

Professor Lin Shen, director of Peking University Cancer Hospital gastroenterology department, is the principal investigator for this trial. She introduced at the conference, "Pancreatic cancer is a highly malignant tumor, and current patients lack effective standardized treatment methods, with a five-year overall survival rate of only 5%. Every year in China, nearly 1-2% of pancreatic cancer patients carry a KRAS G12C mutation, and the mutation rate in other solid tumors is also around 1%. The clinical data of glecirasib have preliminarily confirmed the efficacy in patients with pancreatic cancer and other solid tumors. Compared with the standard chemotherapy treatment, the ORR of glecirasib is higher, and the safety and tolerance is better. It is expected that glecirasib will accelerate the clinical development in pancreatic cancer and other solid tumors, bringing a better treatment option beyond chemotherapy for patients."

Jacobio continues to explore the application of glecirasib in pancreatic cancer. Glecirasib’s registrational pivotal study for pancreatic cancer was approved by CDE in July 2023, which became the first global pancreatic cancer KRAS G12C registrational clinical study. The study results will be used to submit NDA (New Drug Application) for pancreatic cancer.

Based on the clinical efficacy and safety data from ongoing clinical trials, glecirasib was granted breakthrough therapy designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the pancreatic cancer patients with a KRAS G12C mutation who have progressed after frontline standard care treatment. Pancreatic cancer is a malignant tumor and there is a lack of effective treatment currently. The five-year overall survival rate is only 5%-10%. The BTD will expedite the clinical development of glecirasib and accelerate its early access to the patients.

For more information, please visit the official website of the ASCO (Free ASCO Whitepaper) GI: View Source

Conference Call Information

Jacobio will host a live conference call on Jan. 23, 2024, at 9:30-10:30 (UTC+8). Participants must register in advance of the conference call.
Registration Link: View Source

About Glecirasib
Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of Phase I/II clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. This includes a pivotal clinical trial in NSCLC in China (patients enrollment has been completed); a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with Cetuximab in colorectal cancer, and a registrational pivotal clinical trial in pancreatic cancer.

On January 19, 2024 Starpharma (ASX: SPL, OTCQX: SPHRY) reported the presentation of the positive results from its Phase 2 clinical trial of DEP cabazitaxel at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal (GI) Cancers Symposium[1], which is being held from 18 to 20 January 2024 in San Francisco, US (Press release, Starpharma, JAN 19, 2024, View Source;mc_eid=bf52dd3418 [SID1234639337]). ASCO (Free ASCO Whitepaper) is the world’s leading professional organisation for physicians and oncology professionals. The ASCO (Free ASCO Whitepaper) GI Cancers Symposium is the only global meeting of its kind focusing on the latest innovative science and clinical developments in GI cancer treatment, research, and care. It brings together oncology thought leaders, practising clinicians, novel drug developers, and GI specialists from around the world.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starpharma’s scientific poster presents the key results from the Phase 2 trial of DEP cabazitaxel in patients with advanced gastro-oesophageal cancers, announced on 18 October 2023[2], and additional efficacy data for DEP cabazitaxel in two subgroups of the gastro-oesophageal cohort with different types of cancers: adenocarcinoma and squamous cell carcinoma (SCC). DEP cabazitaxel achieved disease control rates of 100% and 50%, respectively, in these advanced and typically hard-to-treat gastro-oesophageal cancers, which have a one-year survival rate of approximately 20%[3],[4].

The ASCO (Free ASCO Whitepaper) GI Cancers Symposium poster will be presented by Associate Professor David Pinato, a leading Clinician Scientist and Consultant Medical Oncologist at the Imperial College London and an investigator for the DEP cabazitaxel study.

Associate Professor David Pinato, MD, MRCP (UK), MRes, PhD, Clinical Reader and Consultant Medical Oncologist, Director of Developmental Cancer Therapeutics Imperial College London, and Investigator for the trial, said:

"I am excited to share the impressive data on Starpharma’s novel dendrimer formulation of cabazitaxel with the gastrointestinal cancer community at this specialist ASCO (Free ASCO Whitepaper) GI cancers conference.

"DEP cabazitaxel showed very encouraging efficacy signals in hard-to-treat gastro-oesophageal cancers, in addition to prostate cancer and advanced platinum-resistant ovarian cancer. The patients in this trial had a poor prognosis with few treatment options remaining.

"In the study, DEP cabazitaxel was well tolerated, including in patients with high-risk clinical features. A number of our patients experienced reduced cancer-related pain, leading to reduced opiate usage, and other improvements in quality of life.

"Based on the data and my experience with DEP cabazitaxel, it represents a well-tolerated and promising treatment alternative for gastro-oesophageal cancers, with the benefit of less frequent treatment than the standard-of-care taxane option."

The key results from the Phase 2 trial of DEP cabazitaxel demonstrated highly encouraging anti-tumour activity in advanced gastro-oesophageal cancers in multiple anatomic locations (oesophagus, gastro-oesophageal junction and stomach), including a median progression-free survival (PFS) of 4.0 months and a median overall survival (OS) of 8.6 months.

The results for DEP cabazitaxel in advanced gastro-oesophageal cancers compare very favourably to standard-of-care paclitaxel treatment in patients with oesophageal or gastro-oesophageal junction cancers. DEP cabazitaxel achieved clinically meaningful improvements with a more than 50% longer median progression-free survival and a 29% longer median overall survival than published data on paclitaxel administered weekly as a second-line treatment[5].

Despite the majority of patients with gastro-oesophageal cancer in Starpharma’s study being refractory to first-line therapy, DEP cabazitaxel achieved a disease control rate (DCR) of 80% and an objective response rate (ORR) of 30%, including stable disease (SD) for up to 27 weeks and partial responses (PR) for up to 17 weeks in evaluable gastro-oesophageal cancer patients.

The DEP cabazitaxel efficacy results in gastro-oesophageal cancer patients, along with highly encouraging efficacy results in patients with metastatic castrate-resistant prostate cancer and platinum-resistant ovarian cancer, indicate the promising clinical potential of DEP cabazitaxel in multiple cancer types, including cancers for which conventional cabazitaxel is not indicated[6].

As reported previously, DEP cabazitaxel was also well-tolerated, with most treatment-related adverse events (TRAEs) being mild to moderate (Grade 1/2, 83%).

Starpharma Chief Executive Officer, Cheryl Maley, commented:

"We are pleased to present the data on DEP cabazitaxel in gastro-oesophageal cancers at the ASCO (Free ASCO Whitepaper) GI cancers meeting. Starpharma’s dendrimer platform has shown promise in multiple therapeutic areas, and the recent Phase 2 results have clinically validated the effectiveness and safety of Starpharma’s DEP technology, which is designed to improve the therapeutic benefits of drugs while minimising their side effects. We are encouraged by these results and the feedback from patients and clinical trial investigators, which underscore the potential of Starpharma’s DEP technology and its ability to improve treatment outcomes for patients."

View/download the ASX Announcement: DEP cabazitaxel data presentation at ASCO (Free ASCO Whitepaper) GI cancer meeting.

View/download the ASCO (Free ASCO Whitepaper) GI Cancer Symposium poster.

About DEP cabazitaxel

Developed by Starpharma, DEP cabazitaxel is a patented, dendrimer nanoparticle version of conventional cabazitaxel, which is marketed as Jevtana and widely used in the treatment of prostate cancer. Unlike standard cabazitaxel, DEP cabazitaxel is highly water soluble, does not contain toxic detergent-like excipients associated with anaphylaxis, and avoids the need for steroid pre-medication. In both preclinical and clinical studies, DEP cabazitaxel has shown an improved side effect profile, notably markedly reduced bone marrow toxicity demonstrated by lower rates of severe neutropenia, thrombocytopenia, and severe anaemia, which are all reportedly experienced by a significant proportion of patients treated with Jevtana.

On January 19, 2024 Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, reported poster presentations at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA (Press release, Aadi Bioscience, JAN 19, 2024, View Source [SID1234639370]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract and poster presentation details are below:

Title: "Real-world analysis of patients with advanced gastrointestinal (GI) cancers harboring inactivating TSC1 and TSC2 alterations using the Foundation Medicine genomic database"
Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time: January 19, 2024 – 12:30 – 2:00 pm
Abstract: 558
Presenting Author: Dustin Deming, MD

Abstract Highlights:

In a large real-world database of patients with advanced cancer, 1,898 (1.4%) of the 138,671 patients with GI cancers harbored at least one known or likely inactivating alteration in TSC1 or TSC2
TSC1 and/or TSC2 inactivating alterations were present in 6.8% of liver cancers, 1.6% of colorectal cancers, and 0.5% of pancreatic cancers
Across GI malignancies, genes frequently mutated in tumors with wild-type TSC1 and TSC2 were similar to genetic mutations co-occurring in tumors with alterations in TSC1 and/or TSC2
Most TSC1 and/or TSC2 inactivating alterations in liver and pancreatic cancers occurred in the context of low TMB and MSS tumors; whereas increased TMB and MSI signatures were enriched in colorectal cancer with TSC1 and/or TSC2 alterations
Limitations of this exploratory, real-world study include the timing of sampling (at initial diagnosis vs disease progression) and the absence of clinically matched outcomes data. More research is needed to understand the clinical and prognostic implications of these data
The PRECISION 1 study (NCT05103358) is currently enrolling patients with solid tumors harboring TSC1 and/or TSC2 inactivating alterations
Aadi is also presenting Trials-in-Progress (TiP) posters from its PRECISION 1 and NET clinical studies.

Title: " PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic in activating alterations in TSC1 and TSC2"
Session Title: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time: January 19, 2024 – 12:30 – 2:00 pm
Abstract: TPS585
Presenting Author: Dustin Deming, MD

Title: "A phase 2, study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lunch, or pancreas"
Session Title: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time: January 19, 2024 – 12:30 – 2:00 pm
Abstract: TPS601
Presenting Author: Scott Paulson, MD

More information can be found on the ASCO (Free ASCO Whitepaper) GI meeting website.